Growth hormone therapy for heart failure: Swimming against the stream

Journal of Cardiac Failure

Volumn 5, Issue 3, 1999, Pages 269-275

  Saccà, Luigi ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Internal Medicine   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE;

HEART DEVELOPMENT; HEART FAILURE; HEART SIZE; HEART VENTRICLE REMODELING; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0032882096     PISSN: 10719164     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1071-9164(99)90012-X     Document Type: Article

References (62)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham study. N Engl J Med 1990;322:1561-6
2. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ: Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51
3. Anversa P, Ricci R, Olivetti G: Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: A review. J Am Coll Cardiol 1986;7:1140-9
4. Gerdes AM, Capasso JM: Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol 1995;27:849-56
5. Olivetti G, Capasso JM, Meggs LG, Sonnenblick EM, Anversa P: Cellular basis of chronic ventricular remodeling after myocardial infarction in rats. Circ Res 1991;68: 856-69
6. Roberts WC, Ferrans VJ: Pathologic anatomy of the cardiomyopathies. Hum Pathol 1975;6:287-342
7. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P: Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation 1994;89:151-63
8. Tagawa H, Koide M, Sato H, Zile MR, Carabello BA, Cooper G IV: Cytoskeletal role in the transition from compensated to decompensated hypertrophy during adult canine left ventricular pressure overloading. Circ Res 1998;82:751-61
9. Gorcsan J III, Feldman AM, Kormos RL, Mandarino WA, Demetris AJ, Batista RJV: Heterogeneous immediate effects of partial left ventriculectomy on cardiac performance. Circulation 1998;97:839-42
10. McDonald KM, Rector T, Carlyle PF, Francis GS, Cohn JN: Angiotensin-converting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage. J Am Coll Cardiol 1994;24:1762-8
11. Brooks WW, Bing OHL, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH: Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997;96:4002-10
12. Mulder P, Devaux B, Richard V, Henry J-P, Wimart M-C, Thibout E, Macé B, Thuillez C: Early versus delayed angiotensin-converting enzyme inhibition in experimental chronic heart failure. Effects on survival, hemodynamics, and cardiovascular remodeling. Circulation 1997;95: 1314-9
13. Hu K, Gaudron P, Ertl G: Long-term effects of beta-adrenergic blocking agent treatment on hemodynamic function and left ventricular remodeling in rats with experimental myocardial infarction. Importance of timing of treatment and infarct size. J Am Coll Cardiol 1998;31:692-700
14. Foster RE, Johnson DB, Barilla F, Blackwell GG, Orr R, Roney M, Stanley AW Jr, Pohost GM, Dell'Italia LJ: Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction. Am Heart J 1998;136:269-75
15. Spinale FG, Holzgrefe HH, Mukherjee R, Hird RB, Walker JD, Arnim-Barker A, Powell JR, Koster WH: Angiotensin-converting enzyme inhibition and the progression of congestive cardiomyopathy. Effects on left ventricular and myocyte structure and function. Circulation 1995;92: 562-78
16. Daly P, Mettauer B, Rouleau J-L, Cousineau D, Burgess JH: Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. Circulation 1985;71:317-25
17. Zhang X, Nasjletti A, Xu X, Wolin MS, Hintze TH: ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997;95: 176-82
18. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A, for the V-HeFT Cooperative Studies Group: Plasma norepinephrine. plasma renin activity, and congestive heart failure: relations to survival and effects of therapy in V-HeFT II. Circulation 1993;87:40-8 (suppl VI)
19. Grassi G, Cattaneo BM, Seravalle G, Lanfranchi A, Pozzi M, Morganti A, Carugo S, Mancia G: Effects of chronic ACE inhibition on sympathetic nerve traffic and baroreflex control of circulation in heart failure. Circulation 1997;96: 1173-9
20. Tan L-B, Jalil JE, Pick R, Janicki JS, Weber KT: Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991;69:1185-95
21. Dipla K, Mattiello JA, Jeevanandam V, Houser SR, Margulies KB: Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. Circulation 1998;97:2316-22
22. Zafeiridis A, Jeevanandam V, Houser SR, Margulies KB: Regression of cellular hypertrophy after left ventricular assist device support. Circulation 1998;98:656-62
23. Nakatani S, McCarthy PM, Kottke-Marchant K, Harasaki H, James KB, Savage RM, Thomas JD: Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device. J Am Coll Cardiol 1996;27:894-901
24. Saccà L, Cittadini A, Fazio S: Growth hormone and the heart. Endocr Rev 1994;15:555-73
25. Saccà L, Fazio S: Cardiac performance: growth hormone enters the race. Nat Med 1996;2:29-31
26. Saccà L: Growth hormone: a newcomer in cardiovascular medicine. Cardiovasc Res 1997;36:3-9
27. Mathews LS, Enberg B, Norstedt G: Regulation of rat growth hormone receptor gene expression. J Biol Chem 1989;17:9905-10
28. Ito H, Hiroe M, Hirata Y, Motoyoshy T, Adachi S, Masayoshi S, Koike A, Nogami A, Marumo F: Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle-specific genes in cultured rat cardiomyocytes. Circulation 1993;87:1715-21
29. Donath MY, Zapf J, Eppenberger-Eberhardt M, Froesch EF, Eppenberger HM: Insulin-like growth factor-1 stimulates myofibril development and decreases smooth muscle alpha-actin of adult cardiomyocytes. Proc Natl Acad Sci U SA 1994;91:1686-90
30. Li Q, Li B, Wang X, Leri A, Jana KP, Kajstura J, Baserga R, Anversa P: Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilatation, wall stress, and cardiac hypertrophy. J Clin Invest 1997;100:1991-9
31. Darnell JE, Kerr IM, Stark GR: JAK-STAT pathways and transcriptional activation in response to INFs and other extracellular signalling proteins. Science 1994;264: 1415-21
32. Foncea R, Andersson M, Ketterman A, Blakesley V, Sapag-Hagar M, Sugden PH, LeRoith D, Lavandero S: Insulin-like growth factor-I rapidly activates multiple signal transduction pathways in cultured rat cardiac myocytes. J Biol Chem 1997;272:19115-24
33. Ambler GR, Johnston BM, Maxwell L, Gavin JB, Gluckman PD: Improvement of doxorubicin-induced cardiomyopathy in rats treated with insulin-like growth factor-I. J Cardiovasc Res 1993;27:1368-73
34. Duerr RL, Huang S, Miraliakbar HR, Chien K, Ross J Jr: Insulin-like growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995;95:619-27
35. Yang R, Bunting S, Gillett N, Clark R, Jin H: Growth hormone improves cardiac performance in experimental heart failure. Circulation 1995;92:262-7
36. Jin H, Yang R, Gillett N, Clark RG, Ko A, Paoni NF: Beneficial effects of growth hormone and insulin-like growth factor-1 in experimental heart failure in rats treated with chronic ACE inhibition. J Cardiovasc Pharmacol 1995;26:420-5
37. Duerr RL, McKirnan D, Gim RD, Clark RG, Chien KR, Ross J Jr: Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation 1996;93:2188-96
38. Shen Y-T, Wiedmann RT, Lynch JJ, Grossman W, Johnson RG: GH replacement fails to improve ventricular function in hypophysectomized rats with myocardial infarction. Am J Physiol 1996;271:H1721-6
39. Cittadini A, Grossman JD, Napoli R, Katz SE, Strömer H, Smith RJ, Clark R, Morgan JP, Douglas PS: Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 1997;29:1109-16
40. Shen Y-T, Woltmann RF, Appleby S, Prahalada S, Krause SM, Kivilghn SD, Johnson RG, Siegl PK, Lynch JJ. Lack of beneficial effects of growth hormone treatment in conscious dogs during development of heart failure. Am J Physiol 1998;274:H456-66
41. Spinale FG, Houck WV, Pan LC: Growth hormone supplementation with developing congestive heart failure: effects on left ventricular cellular structure and composition, (abstract) Circulation 1998;98:180 (suppl I)
42. Grimm D, Cameron D, Griese DP, Riegger GAJ, Kromer EP: Differential effects of growth hormone on cardiomyocyte and extracellular matrix protein remodeling following experimental myocardial infarction. Cardiovasc Res 1998;40:297-306
43. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM: Cardioprotective effect of insulin-like growth factor-I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A 1995;92:8031-5
44. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw B-A: Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996;335:1182-9
45. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordano A, Guida R, Pardo F, Biondi B, Saccà L: A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996;334:809-14
46. Osterziel KJ, Strohm O, Schuler J, Friedrich M, Hänlein D, Willenbrock R, Anker SD, Poole-Wilson PA, Ranke MB, Dietz R: Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998;351:1233-7
47. Genth-Zotz S, Zotz RJ, Geil S, Meyer J, Darius H: Recombinant growth hormone therapy in patients with ischemic cardiomyopathy. Effects on hemodynamics, left ventricular function and cardiopulmonary exercise capacity. Circulation 1999;99:18-21
48. Strömer H, Cittadini A, Douglas PS, Morgan JP: Exogenously administered growth hormone and IGF-I alter intracellular calcium handling and enhance cardiac performance: in vitro evaluation in the isolated isovolumic buffer perfused rat heart. Circ Res 1996;79:227-36
49. 2+ through a wortmannin-sensitive pathway. Studies in rat and ferret isolated muscles. Circ Res 1998;83:50-9
50. Isgaard J, Bergh C-H, Caidahl K, Lomsky M, Hjalmarson ÅA, Bengtsson B-Å: A placebo-controlled study of growth hormone ion patients with congestive heart failure. Eur Heart J 1998;19:1704-11
51. Tanaka N, Ryoke T, Hongo M, Mao L, Rockman HA, Clark RG, Ross J Jr: Effects of growth hormone and IGF-I on cardiac hypertrophy and gene expression in mice. Am J Physiol 1998;275:H393-9
52. Redaelli G, Malhotra A, Li B, Li P, Sonnenblick EH, Hofmann PA, Anversa P: Effects of constitutive overexpression of insulin-like growth factor-1 on the mechanical characteristics and molecular properties of ventricular myocytes. Circ Res 1998;82:594-603
53. Cittadini A, Strömer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS: Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation 1996;93:800-9
54. Bruel A, Oxlund H: The effect of long-term growth hormone administration on the collagen concentration, relative amounts of type I and III collagen and pyridinoline collagen cross-links in rat hearts. Growth Hormone IGF Res 1998;8:328 (abstr)
55. Mayoux E, Ventura-Clapier R, Timsit J, Béhar-Cohen F, Hoffmann C, Mercadier J-J: Mechanical properties of rat cardiac skinned fibers are altered by chronic growth hormone hypersecretion. Circ Res 1993;72:57-64
56. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR: Changes in gene expression in the intact human heart. Downregulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997;100:2315-24
57. Tajima M, Weinberg EO, Bartunek J, Jin H, Yang R, Paoni NF, Lorell BH: Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. Circulation 1999;99:127-34
58. Iannini JP, Houck WV, Pan LC, Kribbs SB, Clair MJ, Krombach RS, Merritt WM, Pine C, Mukherjee R, Spinale FG: Growth hormone supplementation with developing congestive heart failure: effects on left ventricular myocyte contractile processes. Circulation 1998;98:13 (abstr)
59. 2+ release channels (ryanodine receptors) and enhances cardiac function in cardiomyopathic hamsters. Cardiovasc Res 1998;40:64-73
60. Capaldo B, Lembo G, Rendina V, Vigorito C, Guida R, Cuocolo A, Fazio S, Saccà L: Sympathetic deactivation by growth hormone treatment in patients with dilated cardiomyopathy. Eur Heart J 1998;19:623-7
61. Niebauer J, Pflaum C-D, Clark AL, Strasburger CJ, Hooper J, Poole-Wilson PA, Coats AJS, Anker SD: Deficient insulin-like growth factor-I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. Am J Coll Cardiol 1998; 32:393-7
62. Sverrisdóttir YB, Elam M, Herlitz H, Bengtsson B-Å, Johannsson G: Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. J Clin Endocrinol Metab 1998;83:1881-5